Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
Update on Pandemrix™ and interim Finnish report on narcolepsy
GSK is aware of today's interim report by the Finnish National narcolepsy committee on their investigation into reported cases of narcolepsy in Finland.
Read more -
GSK and Actelion discontinue clinical development of almorexant
GlaxoSmithKline (GSK) and Actelion Ltd (SIX: ATLN) today announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has be...
Read more -
GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication
GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug App...
Read more -
GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma
GlaxoSmithKline (GSK) announced today the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation. The studies will separatel...
Read more -
Regulatory update - GSK and Valeant receive positive opinion in Europe from the CHMP for Trobalt (retigabine)
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International, Inc. (NYSE & TSX: VRX) announced today that the European Medicines Agency's Committee for Medicinal Products for...
Read more -
GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication
GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968 (`968), in ambulant bo...
Read more -
GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza
GlaxoSmithKline (GSK) announced today that the first patient has received treatment in a pivotal Phase III study of hospitalised patients with influenza which compares intraveno...
Read more -
GlaxoSmithKline announces Q4 2010 legal charge
GlaxoSmithKline (GSK) today announces that it expects to record a legal charge for the fourth quarter of 2010 of £2.2 billion ($3.4 billion) (equating to an after tax cost of £1...
Read more -
GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK’786, formerly Traficet-EN™, for the treatment of Crohn’s disease
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing...
Read more -
GlaxoSmithKline and DENTSPLY International sign global agreement to create a portfolio of co-branded professional oral care products
GlaxoSmithKline (GSK) and DENTSPLY International, a global leader in professional dental products, today announced that they have entered into an agreement to create a portfolio...
Read more -
GSK responds to 60 Minutes
GlaxoSmithKline [GSK] issued the following response regarding a 60 Minutes program on January 2 that focused on a manufacturing facility in Puerto Rico which was formerly owned ...
Read more -
GlaxoSmithKline and Theravance commence MABA Phase IIb COPD study
GlaxoSmithKline (GSK) and Theravance (NASDAQ: THRX) announced today that the first patient has started treatment with an investigational inhaled bifunctional compound GSK961081...
Read more -
GlaxoSmithKline and Impax Pharmaceuticals enter global agreement to develop and commercialise a late stage compound for Parkinson’s Disease
GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (Impax), today announced an agreement for the development and commercial...
Read more -
Andrew Witty appointed Lead Non-Executive Board Member for the Department for Business, Innovation and Skills (BIS)
The UK Government today announced that Andrew Witty has been appointed as the Lead Non-Executive Board Member for the Department for Business, Innovation and Skills. This appoin...
Read more -
GSK to strengthen Nutritional Healthcare business with acquisition of Maxinutrition
GlaxoSmithKline (GSK) and Maxinutrition Group Holdings Limited today announced they have entered into an agreement for GSK to acquire Maxinutrition, a UK company that manufactur...
Read more -
Phase III study in HER2-positive advanced breast cancer shows overall survival benefit when Tykerb is combined with paclitaxel
In a blinded, randomised, Phase III study, women with previously untreated HER2-positive metastatic breast cancer achieved a statistically-significant improvement in overall sur...
Read more -
Data from Tykerb investigational phase III studies in neo-adjuvant HER2-positive breast cancer presented at breast cancer symposium
Topline results were presented today from two Phase III studies examining the effect of Tykerb (lapatinib) in the neo-adjuvant setting of HER2-positive breast cancer.i, ii The c...
Read more -
GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals in China
GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire Nanjing MeiRui Pharma Co., Ltd (MeiRui) for a cash consideration of approximately $70 ...
Read more -
GlaxoSmithKline and Human Genome Sciences announce FDA extension of Benlysta® PDUFA target date to 10th March 2011
GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User...
Read more -
Avodart reviewed by FDA advisory committee for prostate cancer risk reduction
GlaxoSmithKline (NYSE: GSK) today announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplementa...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
